Cargando…

Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: A patient-rated evaluation

INTRODUCTION: Functional recovery is the contemporary treatment goal in Major Depressive Disorder (MDD). Although consistency among physician and patient expectations may influence the therapeutic result (Demyttenaere K et al, 2011), patients’ perceptions are not always fully captured. Vortioxetine,...

Descripción completa

Detalles Bibliográficos
Autores principales: Galanopoulos, A., Tsiolka, E., Ntounas, P., Mpelimpasakis, D., Karakoutas, D., Sidiropoulos, N., Mpougiouklis, I., Kyziridis, K., Papalexi, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471128/
http://dx.doi.org/10.1192/j.eurpsy.2021.895
_version_ 1784788999216300032
author Galanopoulos, A.
Tsiolka, E.
Ntounas, P.
Mpelimpasakis, D.
Karakoutas, D.
Sidiropoulos, N.
Mpougiouklis, I.
Kyziridis, K.
Papalexi, E.
author_facet Galanopoulos, A.
Tsiolka, E.
Ntounas, P.
Mpelimpasakis, D.
Karakoutas, D.
Sidiropoulos, N.
Mpougiouklis, I.
Kyziridis, K.
Papalexi, E.
author_sort Galanopoulos, A.
collection PubMed
description INTRODUCTION: Functional recovery is the contemporary treatment goal in Major Depressive Disorder (MDD). Although consistency among physician and patient expectations may influence the therapeutic result (Demyttenaere K et al, 2011), patients’ perceptions are not always fully captured. Vortioxetine,a multimodal antidepressant, has shown encouraging data in achieving functional recovery, improving both mood and cognitive symptoms (Mahableshwarkar AR et al, 2015). OBJECTIVES: The aim of the study was to assess the effectiveness of vortioxetine on mood symptoms, cognitive symptoms and functionality, assessed by patient-rated tools, in MDD outpatients in Greece. METHODS: In this non-interventional study, vortioxetine was administered as flexible dosing (5-20 mg/d). Mood symptoms, cognitive symptoms and functioning were assessed by the patient-rated scales PHQ-9, PDQ-D and SDS respectively, at baseline, 1 and 3 months. Repeated measures analysis of variance and t-test were used for the statistical analyses. RESULTS: 336 patients participated in the study. PHQ-9 score ±SD decreased from 16.1±5.3, to 10.0±5.7 and 4.6±4.5, PDQ-D score ±SD decreased from 37.3±16.6 to 23.1±14.8 and 12.0±10.6, SDS Score ±SD decreased from 18.7±5.3 to 12.9±5.9 and to 7.8±6.5, at baseline, 1 and 3 months, respectively. The 3 SDS subscales: work/school life improved from 5.8±2.4 to 4.2±2.2 and 2.6±2.2, social life improved from 6.6±2.0 to 4.5±2.2 and 2.7±2.3 and family life improved from 6.3±2.0 to 4.3±2.1 and 2.6±2.3 -baseline, 1 and 3 months, respectively (p<0.001 for all paired comparisons). CONCLUSIONS: MDD patients in Greece treated with vortioxetine significantly improved on mood symptoms, cognitive symptoms and functioning, enriching the already published efficacy data which is mostly based on clinician-rated scales. CONFLICT OF INTEREST: A. Galanopoulos and E. Papalexi are full-time employees in Lundbeck Hellas.
format Online
Article
Text
id pubmed-9471128
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-94711282022-09-29 Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: A patient-rated evaluation Galanopoulos, A. Tsiolka, E. Ntounas, P. Mpelimpasakis, D. Karakoutas, D. Sidiropoulos, N. Mpougiouklis, I. Kyziridis, K. Papalexi, E. Eur Psychiatry Abstract INTRODUCTION: Functional recovery is the contemporary treatment goal in Major Depressive Disorder (MDD). Although consistency among physician and patient expectations may influence the therapeutic result (Demyttenaere K et al, 2011), patients’ perceptions are not always fully captured. Vortioxetine,a multimodal antidepressant, has shown encouraging data in achieving functional recovery, improving both mood and cognitive symptoms (Mahableshwarkar AR et al, 2015). OBJECTIVES: The aim of the study was to assess the effectiveness of vortioxetine on mood symptoms, cognitive symptoms and functionality, assessed by patient-rated tools, in MDD outpatients in Greece. METHODS: In this non-interventional study, vortioxetine was administered as flexible dosing (5-20 mg/d). Mood symptoms, cognitive symptoms and functioning were assessed by the patient-rated scales PHQ-9, PDQ-D and SDS respectively, at baseline, 1 and 3 months. Repeated measures analysis of variance and t-test were used for the statistical analyses. RESULTS: 336 patients participated in the study. PHQ-9 score ±SD decreased from 16.1±5.3, to 10.0±5.7 and 4.6±4.5, PDQ-D score ±SD decreased from 37.3±16.6 to 23.1±14.8 and 12.0±10.6, SDS Score ±SD decreased from 18.7±5.3 to 12.9±5.9 and to 7.8±6.5, at baseline, 1 and 3 months, respectively. The 3 SDS subscales: work/school life improved from 5.8±2.4 to 4.2±2.2 and 2.6±2.2, social life improved from 6.6±2.0 to 4.5±2.2 and 2.7±2.3 and family life improved from 6.3±2.0 to 4.3±2.1 and 2.6±2.3 -baseline, 1 and 3 months, respectively (p<0.001 for all paired comparisons). CONCLUSIONS: MDD patients in Greece treated with vortioxetine significantly improved on mood symptoms, cognitive symptoms and functioning, enriching the already published efficacy data which is mostly based on clinician-rated scales. CONFLICT OF INTEREST: A. Galanopoulos and E. Papalexi are full-time employees in Lundbeck Hellas. Cambridge University Press 2021-08-13 /pmc/articles/PMC9471128/ http://dx.doi.org/10.1192/j.eurpsy.2021.895 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Galanopoulos, A.
Tsiolka, E.
Ntounas, P.
Mpelimpasakis, D.
Karakoutas, D.
Sidiropoulos, N.
Mpougiouklis, I.
Kyziridis, K.
Papalexi, E.
Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: A patient-rated evaluation
title Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: A patient-rated evaluation
title_full Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: A patient-rated evaluation
title_fullStr Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: A patient-rated evaluation
title_full_unstemmed Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: A patient-rated evaluation
title_short Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: A patient-rated evaluation
title_sort improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: a patient-rated evaluation
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471128/
http://dx.doi.org/10.1192/j.eurpsy.2021.895
work_keys_str_mv AT galanopoulosa improvementsinmoodsymptomscognitivesymptomsandfunctioninginoutpatientswithmddingreecetreatedwithvortioxetineapatientratedevaluation
AT tsiolkae improvementsinmoodsymptomscognitivesymptomsandfunctioninginoutpatientswithmddingreecetreatedwithvortioxetineapatientratedevaluation
AT ntounasp improvementsinmoodsymptomscognitivesymptomsandfunctioninginoutpatientswithmddingreecetreatedwithvortioxetineapatientratedevaluation
AT mpelimpasakisd improvementsinmoodsymptomscognitivesymptomsandfunctioninginoutpatientswithmddingreecetreatedwithvortioxetineapatientratedevaluation
AT karakoutasd improvementsinmoodsymptomscognitivesymptomsandfunctioninginoutpatientswithmddingreecetreatedwithvortioxetineapatientratedevaluation
AT sidiropoulosn improvementsinmoodsymptomscognitivesymptomsandfunctioninginoutpatientswithmddingreecetreatedwithvortioxetineapatientratedevaluation
AT mpougiouklisi improvementsinmoodsymptomscognitivesymptomsandfunctioninginoutpatientswithmddingreecetreatedwithvortioxetineapatientratedevaluation
AT kyziridisk improvementsinmoodsymptomscognitivesymptomsandfunctioninginoutpatientswithmddingreecetreatedwithvortioxetineapatientratedevaluation
AT papalexie improvementsinmoodsymptomscognitivesymptomsandfunctioninginoutpatientswithmddingreecetreatedwithvortioxetineapatientratedevaluation